Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» BeiGene
BeiGene
BeiGene dives in on natural killer cells with discovery pact for small biotech's stem cell-based platform
Endpoints
Wed, 06/9/21 - 11:09 am
BeiGene
China
natural killer cells
cell therapy
Shoreline Biosciences
BeiGene’s Tislelizumab Improves Survival in Esophageal Cancer Study
BioSpace
Thu, 01/28/21 - 11:10 pm
BeiGene
monoclonal antibodies
tislelizumab
clinical trials
esophageal cancer
BeiGene, Novartis in pact to develop tislelizumab for cancer settings
Seeking Alpha
Mon, 01/11/21 - 06:56 pm
Novartis
BeiGene
tiselizumab
cancer
drug development
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
Sun, 12/6/20 - 07:15 pm
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
$200M investment to advance clinical programs for Ambrx
MedCity News
Mon, 11/23/20 - 10:18 pm
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb
BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
Endpoints
Tue, 11/17/20 - 11:00 am
BeiGene
metastatic non-small cell lung cancer
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
Mon, 09/21/20 - 10:26 am
ESMO
BeiGene
urothelial cancer
BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies
Pharmaceutical Business Review
Fri, 08/28/20 - 10:26 am
BeiGene
SInglomics
COVID-19
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
Endpoints
Mon, 07/20/20 - 10:29 am
China
BeiGene
Assembly Biosciences
hepatitis B
Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale
Bloomberg
Mon, 07/13/20 - 11:07 am
China
BeiGene
Amgen
NASDAQ
Important catalysts approach for smaller biotechs
EP Vantage
Wed, 06/24/20 - 10:35 am
BeiGene
Turning Point Therapeutics
Intra-Cellular Therapies
Immunovant
Caplyta
Brukinsa
repotrectinib
IMVT-1401
clinical trials
BeiGene reports positive Phase III interim analysis for lung cancer drug
MedCity News
Wed, 04/15/20 - 10:41 am
BeiGene
clinical trials
immunotherapy
lung cancer
tislelizumab
non-squamous non-small cell lung cancer
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BioSpace
Thu, 01/23/20 - 12:22 pm
BeiGene
tiselizumab
non-small cell lung cancer
Merck
Keytruda
Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Fierce Pharma
Thu, 01/23/20 - 12:12 pm
Amgen
Astellas
Japan
BeiGene
China
BeiGene lung cancer treatment meets main goal in late-stage study
Reuters
Tue, 01/21/20 - 11:53 am
BeiGene
cancer
lung cancer
clinical trials
tislelizumab
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Xtalks
Fri, 01/3/20 - 10:51 pm
Amgen
BeiGene
oncology
China
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Pharmaforum
Fri, 01/3/20 - 09:45 am
Boehringer Ingelheim
China
BeiGene
drug manufacturing
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
Thu, 01/2/20 - 11:57 pm
FDA
drug approvals
cancer
drug launches
AstraZeneca
Enhertu
Padcev
Seattle Genetics
BeiGene
Brukinsa
Corporate and regulatory developments over the Christmas period
EP Vantage
Thu, 01/2/20 - 11:39 pm
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
Sat, 11/30/19 - 11:22 pm
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »